From https://projects.propublica.org/docdollars. © Copyright 2013 Pro Publica Inc.
Boehringer Ingelheim
Boehringer Ingelheim, based in Ingelheim, Germany, agreed to pay $95 million in October 2012 to resolve allegations that it improperly promoted the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drugs Atrovent and Combivent, and the hypertension drug Micardis. In 2014, the company agreed to pay $650 million to settle thousands of lawsuits alleging that it did not properly disclose side effects of its blood thinner Pradaxa.
Boehringer Ingelheim began reporting payments for consulting, speaking, meals, travel and educational items as of January 2013. It also reports research payments in a separate report.
Boehringer Ingelheim's 2013 U.S. sales: $7.7 billion. Source: IMS Health.
See all Boehringer Ingelheim payments, or visit Boehringer Ingelheim's transparency page.
Notable drugs
- Spiriva (Bronchoplasm caused by emphysema, chronic bronchitis, or COPD)
- Micardis (High blood pressure)
- Pradaxa (Blood clots, reduces risk of stroke)
- Combivent (COPD)
- Atrovent (Chronic bronchitis, emphysema, asthma attacks)
- Aggrenox (Prevents strokes in patients with blood flow disorders or blood clots)
- Catapres (High blood pressure, ADHD)
- Tradjenta (Type 2 diabetes)
- Gilotrif (Metastatic non-small cell lung cancer)
- Mirapex (Parkinson disease, restless legs syndrome)
- Viramune (HIV)
- Aptivus (HIV)
Payment Reports
2013 Jan. to Dec.
| Avg. Quarterly | Total | |
|---|---|---|
| Research | $19,114,908 | $76,459,631 |
| $19,114,908 | $76,459,631 |
2013 Jan. to Dec.
| Avg. Quarterly | Total | |
|---|---|---|
| Speaking | $3,125,340 | $12,501,361 |
| Meals | $1,475,746 | $5,902,982 |
| Combination | $665,949 | $2,663,794 |
| Expenses | $405,881 | $1,623,525 |
| Items, Gifts | $8,784 | $35,135 |
| Adjustment | -$5,024 | -$20,096 |
| $5,676,675 | $22,706,702 |
Total Payments by State
| State | Total |
|---|---|
| Florida | $9,995,490 |
| Texas | $8,948,341 |
| California | $8,214,744 |
| South Carolina | $6,688,606 |
| Ohio | $5,216,907 |
| Pennsylvania | $4,501,421 |
| New York | $4,331,902 |
| North Carolina | $4,097,218 |
| Illinois | $3,211,224 |
| Georgia | $2,994,324 |
| Virginia | $2,602,970 |
| Missouri | $2,464,794 |
| Massachusetts | $2,399,868 |
| Colorado | $2,399,653 |
| Arizona | $2,261,125 |
| Connecticut | $2,245,419 |
| New Jersey | $2,029,784 |
| Michigan | $2,024,035 |
| Alabama | $1,969,441 |
| Maryland | $1,950,416 |
| Minnesota | $1,811,513 |
| Tennessee | $1,712,745 |
| Oregon | $1,626,885 |
| Washington | $1,536,687 |
| Kentucky | $1,146,402 |
| Indiana | $1,111,164 |
| Louisiana | $1,107,333 |
| Oklahoma | $1,042,339 |
| Utah | $784,576 |
| West Virginia | $603,962 |
| Nebraska | $583,017 |
| Nevada | $500,623 |
| Idaho | $476,841 |
| Rhode Island | $456,532 |
| Mississippi | $450,571 |
| Iowa | $390,489 |
| Wisconsin | $389,373 |
| Kansas | $376,769 |
| Montana | $302,453 |
| South Dakota | $300,705 |
| Maine | $287,032 |
| Arkansas | $258,074 |
| New Mexico | $237,873 |
| New Hampshire | $202,926 |
| Delaware | $173,068 |
| Puerto Rico | $164,311 |
| District of Columbia | $145,886 |
| Hawaii | $144,852 |
| Alaska | $142,791 |
| Vermont | $78,674 |
| North Dakota | $68,342 |
| Wyoming | $2,574 |
| [Unknown State] | $1,244 |
What Companies Disclose
See which services pharmaceutical companies report paying health practitioners for.
Big Pharma’s Big Fines
Drug companies have paid billions to the Department of Justice to resolve allegations of health care fraud. See some of the biggest settlements.
